Publications by authors named "Marije Overdijk"

Claim this Profile
C
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.
Hilma J van der Horst, Tamás Csikós, Marjolein Quik, Jort J van der Schans, Klaas de Lint, Marije B Overdijk

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells.
Mandy Gruijs, Rens Braster, Marije B Overdijk, Tessa Hellingman, Sandra Verploegen

J Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
Hilma J van der Horst, Anne T Gelderloos, Martine E D Chamuleau, Esther C W Breij, Sonja Zweegman, Marije B Overdijk

Blood Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.
Hilma J van der Horst, Simone C Oostindie, Saskia A G M Cillessen, Anne T Gelderloos, Marije B Overdijk

Hemasphere· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Marije B Overdijk, Kristin Strumane, Frank J Beurskens, Antonio Ortiz Buijsse, Claudine Vermot-Desroches

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.
Simone C Oostindie, Hilma J van der Horst, Laurens P Kil, Kristin Strumane, Marije B Overdijk

Blood Cancer J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
Marije B Overdijk, J H Marco Jansen, Maaike Nederend, Jeroen J Lammerts van Bueren, Richard W J Groen

J Immunol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, Marjolein van Egmond, Jeroen J Lammerts van Bueren

MAbs· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crosstalk between human IgG isotypes and murine effector cells.
Marije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, Tom Vink, Jeanette H W Leusen

J Immunol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Marije B Overdijk

Neoplasia· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Richard W J Groen, Martin F M de Rooij, Kinga A Kocemba, Rogier M Reijmers, Anneke de Haan-Kramer, Marije B Overdijk

Haematologica· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Marije B Overdijk, Sandra Verploegen, Jeroen H van den Brakel, Jeroen J Lammerts van Bueren, Tom Vink

J Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp70 vaccination-induced antibodies recognize B cell epitopes in the cell wall of Mycobacterium avium subspecies paratuberculosis.
Wiebren Santema, Peter van Kooten, Aad Hoek, Mariska Leeflang, Marije Overdijk

Vaccine· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Searching for proteins of Mycobacterium avium subspecies paratuberculosis with diagnostic potential by comparative qualitative proteomic analysis of mycobacterial tuberculins.
Wiebren Santema, Marije Overdijk, Judith Barends, Jeroen Krijgsveld, Victor Rutten

Vet Microbiol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.
Richard W J Groen, Monique E C M Oud, Esther J M Schilder-Tol, Marije B Overdijk, Derk ten Berge

Cancer Res· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterial 70 kD heat-shock protein is an effective subunit vaccine against bovine paratuberculosis.
Ad Koets, Aad Hoek, Merel Langelaar, Marije Overdijk, Wiebren Santema

Vaccine· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine gene expression profiles of bovine dendritic cells after interaction with Mycobacterium avium ssp. paratuberculosis (M.a.p.), Escherichia coli (E. coli) or recombinant M.a.p. heat shock protein 70.
Merel F M Langelaar, Corinna N Weber, Marije B Overdijk, Kerstin E Müller, Ad P Koets

Vet Immunol Immunopathol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis